A Phase 3 interventional study of Ravulizumab and Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (PNH), sponsored by Alexion Pharmaceuticals, Inc.. Completed at 120 sites in 26 countries. Per ClinicalTrials.gov, last updated 2024-05-14.
Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Hemoglobinuria, Paroxysmal by AstraZeneca — 3 open to participants now, 7 under way, 2 of them phase 3. Hemoglobinuria, Paroxysmal · AstraZeneca.
Among the 35 studies in Hemoglobinuria, Paroxysmal by AstraZeneca, this one has the largest enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2016, is one of 12 in phase 3, and was the 14th registered.
191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.
Browse Hemoglobinuria, Paroxysmal studies →3 of the 35 studies in Hemoglobinuria, Paroxysmal by AstraZeneca are open now, in 8 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Korea, Republic of
Alexion Pharmaceuticals, Inc. · Sites in Canada, France, United Kingdom
Ages 12–17
Alexion Pharmaceuticals, Inc. · Sites in United States, Australia, France and 4 more countries
Women only
By country, each count listing its studies:
Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 8 · Phase 3 12 · Phase 4 2
First in 2004; this study’s year is marked. 2 started in 2016.
This study's enrollment of 272 is above the median of 33 across 150 interventional studies indexed under Hemoglobinuria, Paroxysmal.
Median enrollment 26 across the 23 interventional studies, 75 across the 10 observational. Of the 26 that completed or were terminated, 18 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Alexion Pharmaceuticals, Inc., one of the names counted as AstraZeneca. Under that name alone:
Alexion Pharmaceuticals, Inc. is the lead sponsor of 255 studies on the registry; 23 are open to participants now.
Of its 101 completed or terminated interventional studies of FDA-regulated products, 75 (74%) have results posted.
1 of the studies in Hemoglobinuria, Paroxysmal by AstraZeneca that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06449001Phase 3Alexion Pharmaceuticals, Inc.Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis | 2027-05-28 |
Add it to your calendar (.ics) → With an account.
Among the 35 studies in Hemoglobinuria, Paroxysmal by AstraZeneca, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study was to assess the noninferiority of ravulizumab compared to eculizumab in adult participants with PNH who had never been treated with a complement inhibitor (treatment-naïve).
The study consisted of a 4-week screening period and a 26-week randomized treatment period (Primary Evaluation Period). After completion of the 26-week Primary Evaluation Period, all participants had the opportunity to enter the Extension Period, wherein participants will receive ravulizumab for up to 5 years.
Criteria For Patient Cohort Originally Enrolled in ALXN1210-PNH-301 Study: Inclusion Criteria: 1. Male or female ≥18 years of age. 2. PNH diagnosis confirmed by documented by high-sensitivity flow cytometry. 3. Presence of 1 or more of the following PNH-related signs or symptoms within 3 months of screening: fatigue, hemoglobinuria, abdominal pain, shortness of breath (dyspnea), anemia ( \<10 gram/deciliter), history of a major adverse vascular event (including thrombosis), dysphagia, or erectile dysfunction; or history of packed red blood cells (pRBC) transfusion due to PNH. 4. Lactate dehydrogenase (LDH) level ≥1.5 times the at screening. 5. Documented meningococcal vaccination not more than 3 years prior to, or at the time of, initiating study treatment. 6. Female participants of must use highly effective starting at screening and continuing until at least 8 months after the last dose of ravulizumab. 7. Willing and able to give written and comply with study visit schedule. Exclusion Criteria: 1. Treatment with a complement inhibitor at any time. 2. History of bone marrow transplantation. 3. Body weight \<40 kg. 4. Females who are pregnant, breastfeeding, or who have a positive pregnancy test at screening or Day 1. 5. Participation in another interventional clinical study or use of any experimental therapy within 30 days before initiation of study drug on Day 1 in this study or within 5 half-lives of that product, whichever is greater. 6. History of or ongoing major cardiac, pulmonary, renal, endocrine, or hepatic disease that, in the opinion of the investigator or sponsor, would preclude participation. 7. Unstable medical conditions (for example, myocardial ischemia, active gastrointestinal bleed, severe congestive heart failure, anticipated need for major surgery within 6 months of randomization, coexisting chronic anemia unrelated to PNH). Eligibility Criteria For Roll-over Cohort: 1. All participants regardless of age, who are currently receiving ALXN1210 IV in an ongoing ALXN1210 study in patients with PNH 2. Participants must be willing and able to give written informed consent and to comply with all Extension study visits and procedures, including the use of any data collection device(s) to directly record patient data 3. Females of childbearing potential and male patients with female partners of childbearing potential must use highly effective contraception continuing until at least 8 months after the last dose of ravulizumab.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: Ravulizumab
Biological: Ravulizumab · Biological: Eculizumab
All treatments were given as intravenous (IV) infusions. For participants weighing ≥40 to \<60 kilogram (kg): 2400 mg was given as a single loading dose, followed by 3000 mg as maintenance dose. For participants weighing ≥60 to \<100 kg: 2700 mg was given as a loading dose, followed by 3300 mg as maintenance dose. For participants weighing ≥100 kg: 3000 mg was given as a loading dose, followed by 3600 mg as maintenance dose.
All treatments were given as IV infusions. Participants were administered induction doses of 600 mg followed by maintenance doses of 900 mg.
Proportion Of Participants With Normalization Of Lactate Dehydrogenase (LDH) Levels
LDH is an indicator of intravascular hemolysis that occurs in participants with paroxysmal nocturnal hemoglobinuria (PNH). A decrease in LDH from above the upper limit of normal (ULN) to below the ULN indicates reduction (improvement) in hemolysis. Normalization of LDH levels (LDH-N) was LDH levels less than or equal to 1 x ULN, from Day 29 through Day 183. The ULN for LDH is 246 U/L.
Time frame: Day 29 through Day 183
Percentage Of Participants Who Achieved Transfusion Avoidance (TA)
Transfusion avoidance was defined as the percentage of participants who remained transfusion free and did not require a transfusion per protocol-specified guidelines through Day 183.
Time frame: Baseline through Day 183
Percentage Of Participants With Breakthrough Hemolysis (BTH)
Breakthrough hemolysis was defined as at least 1 new or worsening symptom or sign of intravascular hemolysis (fatigue, hemoglobinuria, abdominal pain, shortness of breath \[dyspnea\], anemia \[hemoglobin \<10 gram/deciliter (g/dL)\], major adverse vascular event \[MAVE, including thrombosis\], dysphagia, or erectile dysfunction) in the presence of elevated LDH ≥2 × ULN, after prior LDH reduction to \<1.5 × ULN on therapy.
Time frame: Baseline through Day 183
Percent Change From Baseline In LDH Levels
Baseline is defined as the average of all available assessments of LDH levels prior to first study drug dose. Estimates are based on Mixed Model for Repeated Measures (MMRM) that includes treatment group, history of transfusion (as a categorical variable based on the stratification factor levels) and baseline LDH level (as a continuous variable), study visit and study visit by treatment group interaction. An unstructured covariance structure was used.
Time frame: Baseline, Day 183
Change From Baseline In Quality Of Life As Assessed By The Functional Assessment Of Chronic Illness Therapy (FACIT)-Fatigue
FACIT-Fatigue score ranges from 0 to 52, with a higher score indicating less fatigue. Baseline is defined as the last non-missing value prior to first dose of study drug. Estimates are based on MMRM that includes treatment group, the observed stratification randomization indicators (history of transfusion and LDH) and baseline FACIT-Fatigue level, study visit, and study visit by treatment group interaction. An unstructured covariance structure was used.
Time frame: Baseline, Day 183
Percentage Of Participants With Stabilized Hemoglobin Levels
Stabilized hemoglobin was defined as avoidance of a ≥2 g/dL decrease in hemoglobin level from baseline in the absence of transfusion through Day 183.
Time frame: Baseline through Day 183
24 adult and 2 pediatric participants rolled over from other Alexion ongoing studies of ravulizumab intravenous in participants with PNH into the extension period of this study and received weight-based doses of ravulizumab until end of study.
| Milestone | Ravulizumab/Ravulizumab | Eculizumab/Ravulizumab | Roll-Over Cohort: Ravulizumab - Adults | Roll-Over Cohort: Ravulizumab - Pediatrics |
|---|---|---|---|---|
| Started | 125 | 121 | 0 | 0 |
| Received at least 1 dose of study drug | 125 | 121 | 0 | 0 |
| Completed | 125 | 119 | 0 | 0 |
| Not completed | 0 | 2 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
| Milestone | Ravulizumab/Ravulizumab | Eculizumab/Ravulizumab | Roll-Over Cohort: Ravulizumab - Adults | Roll-Over Cohort: Ravulizumab - Pediatrics |
|---|---|---|---|---|
| Started | 124 | 119 | 24 | 2 |
| Received at least 1 dose of ravulizumab | 124 | 119 | 24 | 2 |
| Completed | 108 | 102 | 22 | 2 |
| Not completed | 16 | 17 | 2 | 0 |
| Withdrew: Death | 4 | 4 | 0 | 0 |
| Withdrew: Withdrawal by subject | 4 | 3 | 0 | 0 |
| Withdrew: Other than specified | 2 | 3 | 2 | 0 |
| Withdrew: Physician decision | 1 | 4 | 0 | 0 |
| Withdrew: Pregnancy | 3 | 1 | 0 | 0 |
| Withdrew: Adverse event | 1 | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 |
LDH is an indicator of intravascular hemolysis that occurs in participants with paroxysmal nocturnal hemoglobinuria (PNH). A decrease in LDH from above the upper limit of normal (ULN) to below the ULN indicates reduction (improvement) in hemolysis. Normalization of LDH levels (LDH-N) was LDH levels less than or equal to 1 x ULN, from Day 29 through Day 183. The ULN for LDH is 246 U/L.
| proportion of participants | Ravulizumab | Eculizumab |
|---|---|---|
| Proportion Of Participants With Normalization Of Lactate Dehydrogenase (LDH) Levels | 0.536 (0.459 to 0.612) | 0.494 (0.417 to 0.570) |
Transfusion avoidance was defined as the percentage of participants who remained transfusion free and did not require a transfusion per protocol-specified guidelines through Day 183.
| percentage of participants | Ravulizumab | Eculizumab |
|---|---|---|
| Percentage Of Participants Who Achieved Transfusion Avoidance (TA) | 73.6 (65.87 to 81.33) | 66.1 (57.68 to 74.55) |
Breakthrough hemolysis was defined as at least 1 new or worsening symptom or sign of intravascular hemolysis (fatigue, hemoglobinuria, abdominal pain, shortness of breath \[dyspnea\], anemia \[hemoglobin \<10 gram/deciliter (g/dL)\], major adverse vascular event \[MAVE, including thrombosis\], dysphagia, or erectile dysfunction) in the presence of elevated LDH ≥2 × ULN, after prior LDH reduction to \<1.5 × ULN on therapy.
| percentage of participants | Ravulizumab | Eculizumab |
|---|---|---|
| Percentage Of Participants With Breakthrough Hemolysis (BTH) | 4.0 (0.56 to 7.44) | 10.7 (5.23 to 16.26) |
Baseline is defined as the average of all available assessments of LDH levels prior to first study drug dose. Estimates are based on Mixed Model for Repeated Measures (MMRM) that includes treatment group, history of transfusion (as a categorical variable based on the stratification factor levels) and baseline LDH level (as a continuous variable), study visit and study visit by treatment group interaction. An unstructured covariance structure was used.
| percent change | Ravulizumab | Eculizumab |
|---|---|---|
| Percent Change From Baseline In LDH Levels | -76.84 (-79.96 to -73.73) | -76.02 (-79.20 to -72.83) |
FACIT-Fatigue score ranges from 0 to 52, with a higher score indicating less fatigue. Baseline is defined as the last non-missing value prior to first dose of study drug. Estimates are based on MMRM that includes treatment group, the observed stratification randomization indicators (history of transfusion and LDH) and baseline FACIT-Fatigue level, study visit, and study visit by treatment group interaction. An unstructured covariance structure was used.
| units on a scale | Ravulizumab | Eculizumab |
|---|---|---|
| Change From Baseline In Quality Of Life As Assessed By The Functional Assessment Of Chronic Illness Therapy (FACIT)-Fatigue | 7.07 (5.55 to 8.60) | 6.40 (4.85 to 7.96) |
Stabilized hemoglobin was defined as avoidance of a ≥2 g/dL decrease in hemoglobin level from baseline in the absence of transfusion through Day 183.
| percentage of participants | Ravulizumab | Eculizumab |
|---|---|---|
| Percentage Of Participants With Stabilized Hemoglobin Levels | 68.0 (59.82 to 76.18) | 64.5 (55.93 to 72.99) |
Collected over Baseline up to Day 2045. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ravulizumab: Primary Evaluation | 0/125 (0%) | 11/125 (8.8%) | 87/125 (69.6%) |
| Eculizumab: Primary Evaluation | 0/121 (0%) | 9/121 (7.4%) | 86/121 (71.1%) |
| Ravulizumab/Ravulizumab: Extension Period | 4/124 (3.2%) | 52/124 (41.9%) | 102/124 (82.3%) |
| Eculizumab/Ravulizumab: Extension Period | 4/119 (3.4%) | 43/119 (36.1%) | 100/119 (84%) |
| Ravulizumab-Adults | 0/24 (0%) | 2/24 (8.3%) | 13/24 (54.2%) |
| Ravulizumab-Pediatrics | 0/2 (0%) | 0/2 (0%) | 0/2 (0%) |
| Event | Ravulizumab: Primary Evaluation | Eculizumab: Primary Evaluation | Ravulizumab/Ravulizumab: Extension Period | Eculizumab/Ravulizumab: Extension Period | Ravulizumab-Adults | Ravulizumab-Pediatrics |
|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/125 | 0/121 | 7/124 | 2/119 | 0/24 | 0/2 |
| PneumoniaInfections and infestations | 0/125 | 1/121 | 5/124 | 6/119 | 0/24 | 0/2 |
| COVID-19Infections and infestations | 0/125 | 0/121 | 6/124 | 3/119 | 0/24 | 0/2 |
| Aplastic anaemiaBlood and lymphatic system disorders | 1/125 | 0/121 | 5/124 | 1/119 | 1/24 | 0/2 |
| CholelithiasisHepatobiliary disorders | 0/125 | 0/121 | 2/124 | 0/119 | 1/24 | 0/2 |
| Cholecystitis acuteHepatobiliary disorders | 0/125 | 0/121 | 1/124 | 4/119 | 0/24 | 0/2 |
| PyrexiaGeneral disorders | 1/125 | 2/121 | 4/124 | 3/119 | 0/24 | 0/2 |
| HaemolysisBlood and lymphatic system disorders | 0/125 | 0/121 | 4/124 | 2/119 | 0/24 | 0/2 |
| Haemolytic anaemiaBlood and lymphatic system disorders | 0/125 | 0/121 | 2/124 | 3/119 | 0/24 | 0/2 |
| PancytopeniaBlood and lymphatic system disorders | 0/125 | 0/121 | 0/124 | 3/119 | 0/24 | 0/2 |
| Event | Ravulizumab: Primary Evaluation | Eculizumab: Primary Evaluation | Ravulizumab/Ravulizumab: Extension Period | Eculizumab/Ravulizumab: Extension Period | Ravulizumab-Adults | Ravulizumab-Pediatrics |
|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 0/125 | 0/121 | 19/124 | 16/119 | 9/24 | 0/2 |
| HeadacheNervous system disorders | 45/125 | 40/121 | 16/124 | 20/119 | 2/24 | 0/2 |
| Upper respiratory tract infectionInfections and infestations | 13/125 | 7/121 | 30/124 | 25/119 | 0/24 | 0/2 |
| NasopharyngitisInfections and infestations | 11/125 | 20/121 | 14/124 | 26/119 | 0/24 | 0/2 |
| PyrexiaGeneral disorders | 6/125 | 11/121 | 22/124 | 18/119 | 2/24 | 0/2 |
| AstheniaGeneral disorders | 0/125 | 0/121 | 0/124 | 0/119 | 4/24 | 0/2 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/125 | 8/121 | 14/124 | 18/119 | 0/24 | 0/2 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 11/125 | 11/121 | 17/124 | 12/119 | 0/24 | 0/2 |
| DiarrhoeaGastrointestinal disorders | 10/125 | 5/121 | 14/124 | 13/119 | 0/24 | 0/2 |
| Abdominal painGastrointestinal disorders | 7/125 | 7/121 | 10/124 | 12/119 | 2/24 | 0/2 |
All participants who received at least 1 dose of study drug.
| Age, Categorical(Participants) | Ravulizumab/Ravulizumab | Eculizumab/Ravulizumab | Roll-Over Cohort: Ravulizumab - Adults | Roll-Over Cohort: Ravulizumab - Pediatrics | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 2 | 2 |
| Between 18 and 65 years | 111 | 103 | 22 | 0 | 236 |
| >=65 years | 14 | 18 | 2 | 0 | 34 |
| Sex: Female, Male(Participants) | Ravulizumab/Ravulizumab | Eculizumab/Ravulizumab | Roll-Over Cohort: Ravulizumab - Adults | Roll-Over Cohort: Ravulizumab - Pediatrics | Total |
|---|---|---|---|---|---|
| Female | 60 | 52 | 12 | 1 | 125 |
| Male | 65 | 69 | 12 | 1 | 147 |
| Ethnicity (NIH/OMB)(Participants) | Ravulizumab/Ravulizumab | Eculizumab/Ravulizumab | Roll-Over Cohort: Ravulizumab - Adults | Roll-Over Cohort: Ravulizumab - Pediatrics | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 5 | 13 | 6 | 2 | 26 |
| Not Hispanic or Latino | 116 | 102 | 0 | 0 | 218 |
| Unknown or Not Reported | 4 | 6 | 18 | 0 | 28 |
| Race (NIH/OMB)(Participants) | Ravulizumab/Ravulizumab | Eculizumab/Ravulizumab | Roll-Over Cohort: Ravulizumab - Adults | Roll-Over Cohort: Ravulizumab - Pediatrics | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 0 | 0 | 2 |
| Asian | 72 | 57 | 1 | 0 | 130 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 4 | 0 | 0 | 6 |
| White | 43 | 51 | 11 | 2 | 107 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 7 | 8 | 12 | 0 | 27 |
Showing the first 100 of 120 sites across 26 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2016 to primary completion in Feb 2023, 74 months.
Of 35 industry-sponsored phase 3 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 41. This study's 74 months is above that.
Counting every sponsor, half of 35 studies reached it within 23 months; a quarter within 15 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ravulizumab
Alexion Pharmaceuticals, Inc. →